Nilambra Dogra et al., 2018-08-09: Dogra et al. report that fenbendazole drives p53 to the mitochondria while suppressing glucose uptake, GLUT transporters and hexokinase II in cancer cells.
Simultaneously, it caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, expression of GLUT transporters as well as hexokinase (HK II) – a key glycolytic enzyme that most cancer cells thrive on.
Nilambra Dogra et al., 2018-08-09: Dogra et al. report that fenbendazole drives p53 to the mitochondria while suppressing glucose uptake, GLUT transporters and hexokinase II in cancer cells. Study type: cell lines plus nu/nu mouse A549 xenografts. N: not stated in the abstract. Country: India (Panjab University, Chandigarh). Dose: micromolar in vitro; 1 mg/mouse orally every second day in vivo. Funder: not stated in the record. Declared conflicts: 'The authors declare no competing interests.' Comparator: untreated cells and vehicle-fed mice. This is p53 translocation to mitochondria, not the Mdm2/MdmX route in the Mrkvova paper; the two documents describe different p53 mechanisms and should not be merged into one sentence. Also filed as FBA-09, FBC-01 (claims C1, C2). Study type: lab.
